Publication Month: Oct 2021 | Report Code: TIPRE00025128 | No. of Pages: 178 | Category: Biotechnology | Status: Published
The market's growth is primarily attributed to the increasing prevalence of liver diseases and the growing focus on developing alternatives for animal testing models. However, the high costs of human liver models and issues with incorporating liver models into existing workflow are hindering the Human Liver Models market growth. The liver is an important organ that performs vital body functions such as synthesis of blood clotting factors, bile production, protein production, and detoxification. Human liver models are used to study the drug's toxicity and enable understanding of the effect of drugs and the progression of liver disease. The rising focus on developing alternatives for the animal testing models is one of the major factors estimated to encourage the growth of the global human liver models in the next few years.
|Market Size Value in||US$ 233.90 million in 2021|
|Market Size Value by||US$ 508.26 million by 2028|
|Growth rate||CAGR of 11.7% from 2021-2028|
|No. of Pages||178|
|No. of Tables||84|
|No. of Charts & Figures||74|
|Historical data available||Yes|
|Segments covered||Type, Application and End User|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The Asia Pacific biopharmaceutical industry was disturbed for a few months of 2020, owing to the COVID-19 outbreak. The COVID-19 pandemic has affected clinical trials in an unparalleled manner due to multiple levels of restrictions imposed to control the spread of infection. However, with the rising demand for products to treat the COVID-19 infection, the biopharmaceutical and pharmaceutical companies in India and China have increased their research activities, which is positively impacting the market growth.
Get more information on this report :
The liver is the largest internal organ in the human body and performs over 500 functions. Liver toxicity is a major concern in risk assessment as the liver is exposed to most xenobiotic compounds and their bioactive metabolites, making it susceptible to chemically induced liver disease. Hepatitis C virus (HCV), chronic hepatitis B virus (HBV), nonalcoholic fatty liver disease (NAFLD), and alcohol-associated liver disease (ALD) are among the leading causes of chronic liver disease. Viral hepatitis continues to be the leading cause of death cases caused by liver failure, and at the same time, the NAFLD has become one of the fastest-growing contributors to liver morbidity and associated mortality. According to the national statistics of the UK, liver diseases have been ranked the fifth-leading cause of death in the country.
Furthermore, these diseases are considered the second-leading cause of death among all digestive diseases in the US. According to the American Association for the Study of Liver Diseases, in 2017, the global burden of liver cancer and cirrhosis had increased. The NAFLDs have an estimated prevalence of ~25% in the general population. Nearly a third of the US population has the NAFLD, and people with Type 2 diabetes mellitus or obesity are disproportionately affected; the number of cases with NAFLD is expected to increase from 83.1 million people in 2015 to 100.9 million by 2030. Thus, a rise in the global prevalence of liver diseases, including chronic and acute diseases and microbial infections, increases the demand for liver models.
Based on type, the human liver models market is further segmented into liver organoids, liver-on-a-chip, 2D models, 3D bioprinting, and others. The liver organoids segment holds the largest share of the market. However, the liver-on-a-chip segment is anticipated to register the highest CAGR during 2021–2028. Advances in liver organoid technology provide models for prenatal development, tissue preservation, and pathologies, which would propel the market growth of this segment in the coming years.
Get more information on this report :
Based on application, the human liver models market is further segmented into educational, drug discovery, and others. The drug discovery segment holds the largest share of the human liver models market; however, the educational segment is anticipated to register the highest CAGR during the forecast period.
Based on end user, the human liver models market is segmented into research institutes, pharmaceutical and biotechnology companies, and others. The pharmaceutical and biotechnology companies segment holds the largest market share. However, the research institutes segment is estimated to register the highest CAGR during the forecast period. The projected market growth for this segment can be attributed to an increase in collaborations between industry and universities for genome research and technological advances in the production of human liver models.
Companies operating in the human liver models market are adopting product innovations strategy to meet the evolving customer demands worldwide, which also permits them to maintain their brand name in the global market.